Prostatic cancer: Hospital-based prostate specific antigen screening
| Autor: | W. Höltl, Mathias Müller, Mariette Vogl |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Male
Oncology PCA3 medicine.medical_specialty Clinical Biochemistry urologic and male genital diseases Prostate cancer Predictive Value of Tests Internal medicine Biopsy Ambulatory Care medicine Humans Mass Screening Mass screening Retrospective Studies medicine.diagnostic_test business.industry Prostatic Neoplasms Cancer Retrospective cohort study General Medicine Rectal examination Middle Aged Prostate-Specific Antigen medicine.disease Hospitals Prostate-specific antigen Austria business |
| Zdroj: | Clinical Biochemistry. 30:357-360 |
| ISSN: | 0009-9120 |
| Popis: | T he utili ty of total prostate specific antigen (PSA) measurements in the follow-up of prostate cancer patients t reated with surgery, hormonal or chemotherapy is well established (1,2). In 1993, PSA originally described as being organ-specific, was approved as a screening marker for prostatic cancer by the American Food and Drug Administration. The combination of PSA concentration, digital rectal examination (DRE), and ultrasonography followed by biopsy in case of suspicion, represents the standard in the detection of prostate cancer at present. The exclusive use of PSA serum levels as a first line screening remains controversial (3). In this retrospective study, our aim was to investigate the number of prostatic cancers detected in our hospital, by analyzing a single PSA concentration in unselected hospitalized and ambulant patients, in order to check the usefulness and the consequences of hospital-based PSA screening. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect